Von Willebrand disease in the Netherlands - Prospective study (WiN-Pro)

Von Willebrand disease in the Netherlands - Prospective study (WiN-Pro) - WiN-Pro

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55831

Enrollment

1300

Registered

2018-09-18

Start date

2019-07-23

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Von Willebrand disease VWD

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Historically lowest VWF:Ag and/or VWF:Act and/or VWF:CB

Exclusion criteria

Exclusion criteria: - Other bleeding disorders present

Design outcomes

Primary

Measure	Time frame
The major-bleeding rate: bleeding that require blood transfusion, desmopressine or factor concentrates or bleeding that lead to death.	—

Secondary

Measure	Time frame
Secundary outcomes are the minor-bleeding rate (all bleeding that do not fulfil the criteria for major-bleeding), bleeding during surgery, Von Willebrand factor levels and the ISTH-BAT score.	—

Countries

Netherlands

Outcome results